Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated varicella-zoster virus vaccine
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
V212 is an investigational, heat-treated (inactivated) varicella-zoster virus (VZV) vaccine developed for the prevention of herpes zoster (shingles), particularly in immunocompromised individuals. The mechanism of action involves stimulating the immune system to generate specific anti-VZV antibodies and cell-mediated immunity against the varicella-zoster virus. Developed by Merck, V212 was designed as a non-live alternative to existing shingles vaccines for patients at higher risk due to immunosuppression. Clinical trials demonstrated that V212 reduced the incidence of confirmed herpes zoster cases by approximately 64% and also decreased complications such as post-herpetic neuralgia and hospitalizations related to herpes zoster. Despite promising results in phase 3 trials, development for this indication has been discontinued[1][2][3][4].
- Other names
- heat-treated varicella-zoster virus vaccineinactivated varicella-zoster vaccineVZV vaccine
02
Targets
TLR9 (Toll-like receptor 9)TLR2 (Toll-like Receptor 2)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on inactivated varicella-zoster virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated varicella-zoster virus vaccine.